Market revenue in 2023 | USD 4,997.0 million |
Market revenue in 2030 | USD 20,972.8 million |
Growth rate | 22.7% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 74.15% in 2023. Horizon Databook has segmented the Japan precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, the government has established an Integrated Community Care System that seamlessly combines healthcare, long-term care, housing, and livelihood support services. This system allows the elderly to receive continuous, high-quality care within their local communities rather than in hospitals, reducing healthcare costs & hospital use and improving health outcomes.
Despite challenges, such as the low percentage of cancer patients receiving personalized drugs based on genomic profiling, R&D is expanding. Japan’s collaboration with other Asian countries under the SCRUM-Japan project, led by the National Cancer Center Hospital East, exemplifies this growth.
In September 2022, the Japanese government approved the "Whole Genome Analysis 2022" Action Plan to integrate personalized medicine into routine medical care, with progress being made in addressing related issues. Since the approval of cancer genetic testing in 2019, Japan has been advancing the social implementation of personalized medicine.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Japan precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account